Aldeyra Therapeutics, Inc. develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for dry eye diseases and allergic conjunctivitis.
Market Cap | 581.502 Million | Shares Outstanding | 58.56 Million | Avg 30-day Volume | 896.252 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.25 |
Price to Revenue | 0.0 | Debt to Equity | 0.1049 | EBITDA | -62.137 Million |
Price to Book Value | 2.6919 | Operating Margin | 0.0 | Enterprise Value | 248.039 Million |
Current Ratio | 11.785 | EPS Growth | 0.009 | Quick Ratio | 11.347 |
1 Yr BETA | 1.096 | 52-week High/Low | 10.03 / 2.36 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -33.0889 | Altman Z-Score | 5.2549 | Free Cash Flow to Firm | -44.97 Million |
Earnings Report | 2023-05-04 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BRADY TODD C PRESIDENT AND CEO |
|
1,455,285 | 2023-02-28 | 3 |
MACHATHA STEPHEN CHIEF DEVELOPMENT OFFICER |
|
0 | 2023-02-28 | 2 |
GREENBERG BRUCE SEE REMARKS |
|
0 | 2023-02-28 | 3 |
|
11,350,085 | 2022-08-09 | 9 | |
|
23,967 | 2022-06-23 | 2 | |
|
69,353 | 2022-06-07 | 1 | |
|
61,930 | 2022-06-07 | 1 | |
|
56,131 | 2022-06-07 | 1 | |
|
61,002 | 2022-06-07 | 1 | |
|
56,131 | 2022-06-07 | 1 | |
REED JOSHUA CHIEF FINANCIAL OFFICER |
|
524,825 | 2022-03-30 | 0 |
|
0 | 2020-06-09 | 0 | |
MCMULLIN DAVID CHIEF COMMERCIAL OFFICER |
|
255,183 | 2020-03-02 | 0 |
CLARK DAVID J CHIEF MEDICAL OFFICER |
|
17,878 | 2019-09-06 | 0 |
TULIPANO STEPHEN J CHIEF FINANCIAL OFFICER |
|
8,563 | 2018-03-06 | 0 |
|
0 | 2016-06-09 | 0 | |
YOUNG SCOTT CHIEF OPERATING OFFICER |
|
0 | 2016-03-16 | 0 |
|
10,358 | 2015-01-01 | 0 | |
|
1,973,389 | 2014-05-07 | 0 | |
|
0 | 2014-05-01 | 0 | |
|
10,358 | 2014-05-01 | 0 | |
|
0 | 2014-05-01 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-03-02 16:22:33 -0500 | 2023-02-28 | A | 238,750 | a | 1,455,285 | direct | -1.6043 | -4.0107 | 5.615 | 5 | -4.0107 | 6 | ||||
2023-03-02 16:22:33 -0500 | 2023-02-28 | A | 250,000 | a | 250,000 | direct | ||||||||||
2023-03-02 16:27:10 -0500 | 2023-02-28 | A | 220,258 | a | 220,258 | direct | ||||||||||
2023-03-02 16:25:46 -0500 | 2023-02-28 | A | 110,028 | d | 110,028 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 22:15:04 UTC | 4.4018 | 0.4182 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 21:45:05 UTC | 4.4018 | 0.4182 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 21:15:03 UTC | 4.4018 | 0.4182 | 1200000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 20:45:04 UTC | 4.4018 | 0.4182 | 1200000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 20:15:04 UTC | 4.4018 | 0.4182 | 1200000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 19:45:04 UTC | 4.4018 | 0.4182 | 1200000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 19:15:04 UTC | 4.4018 | 0.4182 | 1200000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 18:45:04 UTC | 4.4018 | 0.4182 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 18:15:04 UTC | 4.4018 | 0.4182 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 17:45:04 UTC | 4.4018 | 0.4182 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 17:15:03 UTC | 4.4018 | 0.4182 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 16:45:04 UTC | 4.4014 | 0.4186 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 16:15:04 UTC | 4.4014 | 0.4186 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 15:45:04 UTC | 4.4014 | 0.4186 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 15:15:03 UTC | 4.4014 | 0.4186 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 14:45:04 UTC | 4.4014 | 0.4186 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 14:15:04 UTC | 4.4014 | 0.4186 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 13:45:03 UTC | 4.4061 | 0.4139 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 13:15:03 UTC | 4.4061 | 0.4139 | 1300000 |
ALDEYRA THERAPEUTICS INC ALDX | 2023-03-31 12:45:03 UTC | 4.4061 | 0.4139 | 1300000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|